Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund News: Louis Bacon, Paul Singer & Sandler Capital Management

Page 1 of 2

Louis Bacon’s Moore Capital still sizzles despite Wizard exit (Standard)
Louis Bacon’s $15 billion (£9.3 billion) hedge fund Moore Capital boosted profits in its Mayfair office last year despite the loss of star fund manager Greg Coffey. Tory Party donor Bacon saw his European arm generate profits of £36.4 million in 2013, according to a filing at Companies House, with turnover from fees up from £95 million to £140.2 million. Bacon, 58, founded Moore Capital in 1989 after a career on Wall Street and rose to prominence after making a number of successful financial bets linked to the first Gulf War.


Hedge funds slip in September but stock funds fall more (Reuters)
Hedge funds finally have a little something to brag about, losing less money in September than the average mutual stock fund manager, according to data released on Tuesday. The HFRI Fund Weighted Composite Index, a widely watched performance gauge for the $3 trillion global hedge fund industry, slipped 0.4 percent in September, a month when the S&P 500 index fell 1.4 percent. The average U.S. stock mutual fund manager lost 2.92 percent, Lipper data showed. For months, hedge funds have come under fire for delivering lackluster returns as the broader stock market climbed and for charging hefty fees for middling results…

Hong Kong Protest Exceeds Fund Manager’s Wildest Dream (BusinessWeek)
Hong Kong hedge-fund manager and pro-democracy activist Edward Chin says that the scale of student protests that exploded in the city from Sept. 28 exceeded his “wildest dreams.” “I just expected 10,000 people sitting at Chater Garden,” Chin said in an interview this week, referring to plans by the Occupy Central With Love and Peace group. Instead, crowds swelled to as many as 200,000, according to protest leaders. Chin, 46, is one of a group of finance professionals who published open letters to Chinese President Xi Jinping supporting Occupy Central and urging genuine universal suffrage.

Why Northwest Bio Is Shunned by Savvy Health Care Investors (TheStreet)
Washington Post business columnist Steven Pearlstein accused me — falsely — of working with short-selling hedge funds to manipulate stock prices and force small biotech companies like Northwest Biotherapeutics, Inc (NASDAQ:NWBO) out of business. I’ve been a professional business journalist for 25 years, the last 13 years writing about often-crazy and never-boring biotech stocks for TheStreet. I’m accustomed to the controversy that comes with being an opinionated columnist in a volatile sector. TheStreet rebutted Pearlstein’s column so I won’t rehash details, but it raised one glaring question that went unanswered:

Sandler Buys At Ultra-Luxurous N.Y.C. Building (Finalternatives)
A hedge-fund manager has rewarded an investor in Manhattan’s tallest and (arguably) most luxurious apartment tower with a hefty profit. Sandler Capital Management founder Harvey Sandler and his wife have dropped $34 million for a 58th-floor unit bought by Sso Enterprises for $30.55 million just five months ago. Still, Sandler can argue that he got a deal on the 4,483-square-foot pied à terre at One57, which had been listed for $40 million. Sandler’s new home has three bedrooms, five marble-clad bathrooms and panoramic views.

Qalaa’s new structure is ‘the right strategy’: Founder (CNBC)

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!